2022 Saul Hertz, MD Award Winner: Andrew M. Scott, MD, FRACP, FAANMS

The Saul Hertz, MD Award is a lifetime achievement award, recognizing individuals who have made outstanding contributions to radionuclide therapy.  

In 2022, the award was presented to Andrew M. Scott, MD, FRACP, FAANMS. 

Professor Scott is currently, Director, Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia; Laboratory Head, Olivia Newton-John Cancer Research Institute, Melbourne, Australia; Director, Australian Cancer Research Foundation (ACRF) Centre for Translational Cancer Therapeutics and Imaging; Co-Director, Centre for Research Excellence in Brain Cancer, Melbourne, Australia; Professor, Faculty of Medicine, University of Melbourne, Australia; Professor, School of Cancer Medicine, La Trobe University; Professor, Department of Biochemistry and Molecular Biology, Monash University; NHMRC Senior Investigator; Past-President, World Federation of Nuclear Medicine and Biology. A prolific author, he has more than 400 reviewed publications, and 27 book chapters. Among his many awards, in 2017, he was made a Member of the Order of Australia “for significant service to Nuclear Medicine and Cancer Research as an academic, and to Professional Organisations. He is current recipient of more than $10,000,000 of grants from a variety of Australian, Commonwealth and NIH sources, predominantly on the topic or theranostics and molecular imaging.

Professor Scott has made many significant contributions to the field of radionuclide therapy and related nuclear medicine practice over more than 20 years. He has identified and validated novel targets for antibody and peptide-based radionuclide therapy and developed new approaches to combination therapies that have translated into multi-centre and multi-national clinical trials. in the general field of targeted radiotherapy. He has also been pivotal in establishing and leading programs to promote evidence-based clinical trials for targeted radionuclide therapy that are approaching approval stage. He has actively trained in his laboratory, many basic and clinician scientists who have gone on to contribute to the development of Molecular imaging and Theranostics in academia and industry. Finally, he has led major initiatives to promote radionuclide therapy at a global level, through leadership of international committees including the SNMMI Global Initiative and as President of the World Federation of Nuclear Medicine and Biology (2014-2018).

Andrew M. Scott, MD, FRACP, FAANMS